skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Carbon C 14 Selumetinib (Code C111763)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Carbon C 14 Selumetinib

Definition: A radioconjugate containing the orally available selumetinib, an inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) types 1 and 2, labeled with the radioisotope carbon C 14. Upon oral administration, selumetinib selectively inhibits MEK1/2, which prevents the activation of MEK1/2 dependent effector proteins and transcription factors. This leads to an inhibition of cellular proliferation in MEK1/2-overexpressing tumor cells. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in various cancer cells. Selumetinib radiolabeled with carbon C-14 may be used as a radiotracer for pharmacokinetic studies of this agent, including its absorption, distribution, metabolism and excretion (ADME).

Label: Carbon C 14 Selumetinib

NCI Thesaurus Code: C111763 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL454150  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
[14C] Selumetinib
Carbon C 14 Selumetinib

External Source Codes: 
PDQ Closed Trial Search ID 753196
PDQ Open Trial Search ID 753196 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C111763
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom